JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops and sells medicines, specializing in dermatology and urology treatments.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시

Description

JW SHINYAK CORPORATION is a pharmaceutical company engaged in the research, development, production, and sale of medicines and medical supplies. The company specializes in treatments for the clinic market, with a notable focus on dermatology and urology. Its product portfolio includes well-known treatments for hair loss, such as Rogaine and Monad, alongside medications for endocrinology disorders, symptoms related to brain vessel defects, and various bacterial infections. In its research and development activities, JW SHINYAK utilizes proprietary foundational technologies like "DC vacuum technology" and "CTP" to advance its pipeline of bio-medicines. The company also manufactures and distributes a range of healthcare products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-07 00:00
주식등의대량보유상황보고서(일반)
Korean 74.0 KB
2025-02-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2025-02-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2025-02-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2025-02-05 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.1 KB
2024-12-26 00:00
권배락 (무상증자 및 배당)
Korean 3.9 KB
2024-12-20 00:00
자산재평가결과(자율공시)
Korean 8.7 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-12-16 00:00
주요사항보고서(무상증자결정)
Korean 10.1 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.6 KB
2024-12-06 00:00
자산재평가실시결정(자율공시)
Korean 5.0 KB
2024-12-02 00:00
벌금등의부과
Korean 5.8 KB
2024-11-22 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.0 KB
2024-11-22 00:00
증권발행결과(자율공시)
Korean 6.1 KB
2024-11-22 00:00
증권발행결과(자율공시)
Korean 5.7 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.